Mersana Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2016 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Mersana Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2016 to Q2 2024.
  • Mersana Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending June 30, 2024 was $1.57M.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $1.57M +$1.57M Jun 30, 2024 10-Q 2024-08-13
Q4 2023 $0 -$30M -100% Dec 31, 2023 10-Q 2024-08-13
Q3 2023 $0 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $0 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $0 Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $30M +$30M Dec 31, 2022 10-K 2024-02-28
Q4 2021 $0 Dec 31, 2021 10-K 2023-02-28
Q3 2019 $298K -$288K -49.1% Sep 30, 2019 10-Q 2019-11-06
Q2 2019 $288K -$1.39M -82.9% Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $468K +$180K +62.5% Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $459K -$325K -41.5% Dec 31, 2018 10-K 2020-02-28
Q3 2018 $586K -$145K -19.8% Sep 30, 2018 10-Q 2018-11-13
Q2 2018 $1.68M +$1.17M +228% Jun 30, 2018 10-Q 2018-08-14
Q1 2018 $288K Mar 31, 2018 10-Q 2018-05-15
Q4 2017 $784K -$267K -25.4% Dec 31, 2017 10-K 2019-03-08
Q3 2017 $731K Sep 30, 2017 10-Q 2017-11-13
Q2 2017 $513K Jun 30, 2017 10-Q 2017-08-11
Q4 2016 $1.05M Dec 31, 2016 10-K 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.